复星医药(02196)：注射用奈达铂的药品注册申请获国家药监局受理

Core Viewpoint - Fosun Pharma's subsidiary, Gismed (Wuhan) Pharmaceutical Co., Ltd., has received acceptance for the drug registration application of injectable Nedaplatin from the National Medical Products Administration, indicating progress in the company's drug development pipeline [1] Group 1: Drug Development - The drug Nedaplatin is a self-developed chemical drug by the group, intended for the treatment of various cancers including head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophageal cancer, bladder cancer, testicular tumor, ovarian cancer, and cervical cancer [1] - As of July 2025, the cumulative R&D investment for this drug is approximately RMB 5.66 million (unaudited) [1]